New therapeutic approaches for metastatic thyroid carcinoma.

Martin Schlumberger, Eric Baudin

Journal: The Lancet. Oncology 2007;8(2):148-56

PMID: 17267329

Abstract

Treatment of metastatic differentiated thyroid cancer (DTC) includes the use of radioiodine and suppressive thyroid hormone treatment. A third of patients with distant metastases (who have radioiodine uptake, are younger than 40 years, have small metastases, and have well differentiated thyroid tumour) can be cured with radioiodine treatment. For other patients, there are no effective treatment modalities. However, the recent availability of molecularly targeted treatments has led to changes in the treatment strategy for DTC in patients with distant metastases, especially in those who are resistant to radioiodine treatment.

Address: Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, and Faculté de Médecine Paris Sud, Villejuif, France.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.